MX2022005238A - Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. - Google Patents

Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.

Info

Publication number
MX2022005238A
MX2022005238A MX2022005238A MX2022005238A MX2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
lenalidomide
hla
bispecific antibody
Prior art date
Application number
MX2022005238A
Other languages
English (en)
Spanish (es)
Inventor
Christian Klein
Christian Augsberger
Sabine Marion Subklewe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022005238A publication Critical patent/MX2022005238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022005238A 2019-11-05 2020-11-03 Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. MX2022005238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207090 2019-11-05
PCT/EP2020/080763 WO2021089513A1 (en) 2019-11-05 2020-11-03 Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide

Publications (1)

Publication Number Publication Date
MX2022005238A true MX2022005238A (es) 2022-06-08

Family

ID=68468600

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005238A MX2022005238A (es) 2019-11-05 2020-11-03 Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.

Country Status (12)

Country Link
US (1) US20220275093A1 (enExample)
EP (1) EP4054716A1 (enExample)
JP (1) JP2023501276A (enExample)
KR (1) KR20220093323A (enExample)
CN (1) CN115003384A (enExample)
AU (1) AU2020381349A1 (enExample)
BR (1) BR112022008652A2 (enExample)
CA (1) CA3155308A1 (enExample)
IL (1) IL292103A (enExample)
MX (1) MX2022005238A (enExample)
TW (1) TW202132341A (enExample)
WO (1) WO2021089513A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540174A (ja) * 2021-11-01 2024-10-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体および４－１ｂｂ（ｃｄ１３７）アゴニストを用いたがんの治療
WO2024149821A1 (en) * 2023-01-13 2024-07-18 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
JP2026526949A (ja) * 2023-07-31 2026-08-10 メディトックス インク． 抗体及びそれを含む免疫疾患治療用薬学的組成物
WO2025103425A1 (en) * 2023-11-15 2025-05-22 Concept To Medicine Biotech Co., Ltd. Multispecific antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11547696B2 (en) * 2016-10-28 2023-01-10 Children's Hospital Medical Center Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
PE20201149A1 (es) * 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1

Also Published As

Publication number Publication date
JP2023501276A (ja) 2023-01-18
US20220275093A1 (en) 2022-09-01
CN115003384A (zh) 2022-09-02
EP4054716A1 (en) 2022-09-14
IL292103A (en) 2022-06-01
KR20220093323A (ko) 2022-07-05
WO2021089513A1 (en) 2021-05-14
TW202132341A (zh) 2021-09-01
BR112022008652A2 (pt) 2022-07-19
CA3155308A1 (en) 2021-05-14
AU2020381349A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2024013523A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
PH12020552232A1 (en) IL-11 Antibodies
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA202190365A1 (ru) Способы изготовления пакетов-мессенджеров растений
PH12019502283A1 (en) Anti-lag3 antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
NZ767596A (en) Antibodies that bind cd39 and uses thereof
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
PH12020552229A1 (en) Il-11ra antibodies
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MY191649A (en) Antibodies to tigit
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
UA120060C2 (uk) Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
MX2016017393A (es) Diacuerpos heterodimericos biespecificos y sus usos.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
EP4541819A3 (en) Anti-cd3 epsilon antibodies